INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $651 | -58.3% | 35,087 | -75.2% | 0.01% | -53.8% |
| Q2 2023 | $1,562 | +49.9% | 141,219 | +82.1% | 0.01% | +44.4% |
| Q1 2023 | $1,042 | -84.1% | 77,558 | -85.4% | 0.01% | -90.5% |
| Q4 2022 | $6,563 | -99.4% | 530,567 | +532.1% | 0.10% | +533.3% |
| Q3 2022 | $1,171,000 | +107.3% | 83,939 | +141.6% | 0.02% | +114.3% |
| Q1 2022 | $565,000 | -78.0% | 34,745 | -78.0% | 0.01% | -74.1% |
| Q4 2021 | $2,568,000 | +504.2% | 157,663 | +450.6% | 0.03% | +350.0% |
| Q3 2021 | $425,000 | +100.5% | 28,633 | +169.2% | 0.01% | +200.0% |
| Q2 2021 | $212,000 | -49.2% | 10,635 | -41.1% | 0.00% | -66.7% |
| Q1 2021 | $417,000 | -10.9% | 18,055 | -4.6% | 0.01% | +20.0% |
| Q4 2020 | $468,000 | -76.1% | 18,929 | -53.8% | 0.01% | -90.2% |
| Q2 2020 | $1,961,000 | +623.6% | 40,941 | +1104.1% | 0.05% | +363.6% |
| Q2 2019 | $271,000 | +34.8% | 3,400 | +89.3% | 0.01% | -26.7% |
| Q1 2019 | $201,000 | – | 1,796 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |